​

AbbVie (ABBV) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

ABBV Stock Forecast

AbbVie stock forecast is as follows: an average price target of $211.20 (represents a 20.51% upside from ABBV’s last price of $175.26) and a rating consensus of 'Buy', based on 32 wall street analysts offering a 1-year stock forecast.

ABBV Price Target

The average price target for AbbVie (ABBV) is $211.20 based on 1-year price targets from 32 Wall Street analysts in the past 3 months, with a price target range of $226.00 to $203.00. This represents a potential 20.51% upside from ABBV's last price of $175.26.

ABBV Analyst Ratings

Buy

According to 32 Wall Street analysts, AbbVie's rating consensus is 'Buy'. The analyst rating breakdown for ABBV stock is 0 'Strong Buy' (0.00%), 22 'Buy' (68.75%), 10 'Hold' (31.25%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

AbbVie Price Target by Analyst

DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Nov 12, 2024Evan David SeigermanBMO Capital$208.00$201.613.17%18.68%
Oct 31, 2024Evan David SeigermanBMO Capital$228.00$201.5013.15%30.09%
Oct 31, 2024Charlie YangBank of America Securities$210.00$201.504.22%19.82%
Oct 31, 2024Geoff MeachamCitigroup$226.00$201.5012.16%28.95%
Oct 18, 2024Geoff MeachamBank of America Securities$195.00$188.573.41%11.26%
Oct 17, 2024Courtney BreenBernstein$203.00$190.466.58%15.83%
Aug 23, 2024Christopher RaymondRaymond James$209.00$197.355.90%19.25%
Jul 19, 2024Evan SeigermanBMO Capital$214.00$172.0124.41%22.10%
Jun 18, 2024Christopher RaymondRaymond James$190.00$171.3610.88%8.41%
Jun 05, 2024Rajesh KumarHSBC$185.00$162.1414.10%5.56%
May 24, 2024James ShinDeutsche Bank$175.00$156.9611.49%-0.15%
May 17, 2024Louise ChenCantor Fitzgerald$200.00$164.3521.69%14.12%
Apr 29, 2024Evan SeigermanBMO Capital$180.00$158.5813.50%2.70%
Mar 27, 2024Carter GouldBarclays$195.00$179.798.46%11.26%
Jan 29, 2024Tim LugoWilliam Blair$190.00$163.9115.92%8.41%
Nov 09, 2023Christopher RaymondRaymond James$170.00$142.0319.69%-3.00%
Sep 29, 2023Gary NachmanRaymond James$177.00$149.1218.70%0.99%
May 09, 2023Vamil DivanGuggenheim$171.00$147.0116.32%-2.43%
Feb 06, 2023BMO Capital$167.00$145.4914.78%-4.71%
Dec 06, 2022Morgan Stanley$182.00$163.4411.36%3.85%
Nov 18, 2022Credit Suisse$170.00$152.1611.72%-3.00%
Sep 30, 2022Leerink Partners$135.00$142.72-5.41%-22.97%
Aug 24, 2022Argus Research$155.00$137.9112.39%-11.56%
Aug 01, 2022Barclays$160.00$143.5111.49%-8.71%
Jul 14, 2022Terence FlynnMorgan Stanley$191.00$152.1525.53%8.98%
May 24, 2022David RisingerLeerink Partners$140.00$148.03-5.42%-20.12%
May 22, 2022Luisa HectorBerenberg Bank$135.00$151.01-10.60%-22.97%
May 03, 2022Terence FlynnMorgan Stanley$188.00$147.8727.14%7.27%
May 02, 2022Wells Fargo$200.00$146.8836.17%14.12%
Apr 26, 2022Gary NachmanBMO Capital$174.00$157.7210.33%-0.72%
Apr 16, 2022Carter GouldBarclays$174.00$162.317.20%-0.72%
Apr 06, 2022Terence FlynnMorgan Stanley$192.00$168.9113.67%9.55%
Mar 05, 2022Navin JacobUBS$147.00$150.56-2.36%-16.12%
Feb 21, 2022Robyn KarnauskasTruist Financial$160.00$144.0311.09%-8.71%
Feb 06, 2022Vamil DivanMizuho Securities$166.00$140.6518.02%-5.28%
Feb 03, 2022Chris SchottJ.P. Morgan$180.00$140.7327.90%2.70%
Feb 03, 2022Carter GouldBarclays$150.00$140.736.59%-14.41%
Feb 02, 2022Christopher RaymondPiper Sandler$160.00$138.6215.42%-8.71%
Feb 01, 2022Joshua SchimmerEvercore ISI$133.00$137.00-2.92%-24.11%
Jan 29, 2022Andrew BaumCitigroup$155.00$137.9212.38%-11.56%
Jan 18, 2022Steve ScalaCowen & Co.$150.00$136.789.67%-14.41%
Jan 18, 2022Gary NachmanBMO Capital$153.00$136.7811.86%-12.70%
Jan 03, 2022Aaron GalBernstein$155.00$134.0315.65%-11.56%
Dec 08, 2021Mohit BansalWells Fargo$165.00$120.6236.79%-5.85%
Nov 23, 2021Justin SmithSociete Generale$172.00$117.6646.18%-1.86%
Aug 05, 2021David ToungArgus Research$140.00$112.5724.37%-20.12%
Aug 01, 2021Daniel BusbyRBC Capital$135.00$112.9019.57%-22.97%
May 03, 2021Tim AndersonWolfe Research$127.00$110.9114.51%-27.54%

The latest AbbVie stock forecast, released on Nov 12, 2024 by Evan David Seigerman from BMO Capital, set a price target of $208.00, which represents a 3.17% increase from the stock price at the time of the forecast ($201.61), and a 18.68% increase from ABBV last price ($175.26).

AbbVie Price Target by Period

1M3M12M
# Anlaysts-414
Avg Price Target-$218.00$201.29
Last Closing Price$175.26$175.26$175.26
Upside/Downside-100.00%24.39%14.85%

In the current month, the average price target of AbbVie stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to AbbVie's last price of $175.26. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

DateCompanyPrevious RatingNew RatingRating Change
Nov 22, 2024Leerink PartnersOutperformUpgrade
Nov 12, 2024BMO CapitalOutperformOutperformHold
Oct 31, 2024Morgan StanleyOverweightOverweightHold
Oct 31, 2024CitigroupBuyBuyHold
Oct 18, 2024Bank of America SecuritiesNeutralNeutralHold
Oct 17, 2024BMO CapitalOutperformOutperformHold
Oct 17, 2024BernsteinOutperformMarket PerformInitialise
Oct 09, 2024UBSNeutralNeutralHold
Oct 07, 2024Wells FargoBuyBuyHold
Oct 07, 2024Morgan StanleyOverweightOverweightHold
Oct 07, 2024Wells FargoOverweightOverweightHold
Oct 07, 2024BarclaysOverweightOverweightHold
Sep 24, 2024Piper SandlerOverweightOverweightHold
Aug 23, 2024Wells FargoBuyBuyHold
Aug 23, 2024Piper SandlerOverweightOverweightHold
Aug 12, 2024Morgan StanleyOverweightOverweightHold
Jul 26, 2024BarclaysOverweightOverweightHold
Jul 19, 2024BMO CapitalOutperformOutperformHold
Jul 11, 2024Morgan StanleyOverweightOverweightHold
Jul 02, 2024Sandler O'NeillBuyBuyHold
Jul 02, 2024Sandler O'NeilUnderperformUnderperformHold
Jun 18, 2024Piper SandlerOverweightOverweightHold
Jun 05, 2024HSBCBuyUpgrade
May 24, 2024Deutsche BankHoldHoldHold
May 14, 2024Cowen & Co.BuyBuyHold
Apr 29, 2024BMO CapitalOutperformOutperformHold
Mar 27, 2024BarclaysOverweightOverweightHold
Mar 01, 2024OppenheimerPerformPerformHold
Feb 05, 2024BarclaysOverweightOverweightHold
Feb 05, 2024Raymond JamesOutperformOutperformHold
Jan 29, 2024William BlairMarket PerformOutperformUpgrade
Dec 11, 2023Goldman SachsBuyUpgrade
Nov 09, 2023Morgan StanleyEqual-WeightEqual-WeightHold
Oct 30, 2023Morgan StanleyOverweightOverweightHold
Oct 30, 2023BarclaysEqual-WeightOverweightUpgrade
Jul 25, 2023William BlairMarket PerformInitialise
Jun 26, 2023Piper SandlerOverweightNeutralUpgrade
Jun 08, 2023Wolfe ResearchPeer PerformDowngrade
May 10, 2023Cantor FitzgeraldOverweightOverweightHold
May 09, 2023GuggenheimBuyBuyHold
Mar 01, 2023GuggenheimBuyInitialise
Feb 10, 2023Morgan StanleyOverweightEqual-WeightDowngrade
Feb 10, 2023WedbushNeutralDowngrade
Feb 10, 2023Wells FargoOverweightEqual-WeightDowngrade
Feb 10, 2023RBC CapitalOutperformUpgrade
Feb 10, 2023StephensOverweightUpgrade
Feb 10, 2023ScotiabankOutperformUpgrade
Feb 10, 2023Maxim GroupBuyUpgrade
Feb 10, 2023MoffettNathansonMarket PerformDowngrade
Feb 10, 2023Credit SuisseOutperformNeutralDowngrade
Feb 10, 2023SVB LeerinkUnderperformMarket PerformUpgrade
Feb 06, 2023BMO CapitalOutperformOutperformHold
Dec 06, 2022Morgan StanleyOverweightOverweightHold
Nov 18, 2022Credit SuisseOutperformInitialise
Nov 09, 2022Societe GeneraleHoldDowngrade
Sep 30, 2022SVB LeerinkUnderperformUnderperformHold
Aug 24, 2022Argus ResearchBuyBuyHold
Aug 17, 2022NeedhamBuyBuyHold
Aug 01, 2022BarclaysEqual-WeightEqual-WeightHold
Aug 01, 2022Atlantic EquitiesNeutralDowngrade
Jul 29, 2022Piper SandlerOverweightOverweightHold
Jul 29, 2022Cowen & Co.OutperformOutperformHold
Jul 14, 2022Morgan StanleyOverweightOverweightHold
May 24, 2022SVB LeerinkUnderperformInitialise
May 02, 2022Wells FargoOverweightOverweightHold
May 02, 2022Mizuho SecuritiesBuyBuyHold
Apr 30, 2022Piper SandlerOverweightOverweightHold
Apr 28, 2022BMO CapitalOutperformOutperformHold
Apr 26, 2022BMO CapitalBuyBuyHold
Apr 16, 2022BarclaysReduceReduceHold
Feb 28, 2022UBSNeutralDowngrade
Jan 18, 2022BMO CapitalOutperformOutperformHold
Jan 09, 2022Piper SandlerOverweightOverweightHold
Dec 09, 2021Wells FargoOverweightInitialise
Sep 05, 2021Mizuho SecuritiesBuyBuyHold
May 02, 2021Piper SandlerOverweightOverweightHold
Nov 11, 2020BernsteinOutperformInitialise
Sep 29, 2020Morgan StanleyBuyBuyHold

AbbVie's last stock rating was published by Leerink Partners on Nov 22, 2024. The company Upgrade its ABBV rating from "null" to "Outperform".

AbbVie Financial Forecast

AbbVie Revenue Forecast

Dec 27Sep 27Jun 27Mar 27Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20
Revenue-----------------$13.93B$13.87B$12.22B$15.12B$14.81B$14.58B$13.54B$14.89B$14.34B$13.96B$13.01B$13.86B$12.90B
Avg Forecast$18.20B$18.27B$17.67B$14.44B$17.35B$16.83B$16.13B$14.26B$15.88B$15.34B$14.80B$13.08B$14.82B$14.28B$14.02B$11.93B$14.03B$13.72B$13.54B$12.17B$15.33B$14.96B$14.66B$13.61B$14.95B$14.30B$13.63B$12.77B$13.70B$12.72B
High Forecast$18.92B$18.99B$18.37B$15.01B$18.04B$17.50B$16.77B$14.82B$16.50B$15.95B$15.39B$13.53B$14.96B$14.29B$14.02B$11.93B$14.34B$13.83B$14.08B$12.65B$15.83B$14.96B$14.66B$13.61B$14.95B$14.30B$13.63B$12.77B$13.70B$12.72B
Low Forecast$17.80B$17.87B$17.29B$14.12B$16.98B$16.47B$15.78B$13.95B$15.53B$15.01B$14.48B$12.84B$14.71B$14.28B$14.02B$11.93B$13.94B$13.65B$13.25B$11.91B$15.00B$14.96B$14.66B$13.61B$14.95B$14.30B$13.63B$12.77B$13.70B$12.72B
# Analysts4444444433351377491599131313137777915
Surprise %-----------------1.02%1.02%1.00%0.99%0.99%0.99%0.99%1.00%1.00%1.02%1.02%1.01%1.01%

AbbVie's average Quarter revenue forecast for Dec 23 based on 9 analysts is $14.03B, with a low forecast of $13.94B, and a high forecast of $14.34B. ABBV's average Quarter revenue forecast represents a 0.70% increase compared to the company's last Quarter revenue of $13.93B (Sep 23).

AbbVie EBITDA Forecast

Dec 27Sep 27Jun 27Mar 27Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20
# Analysts4444444433351377491599131313137777915
EBITDA-----------------$2.44B$5.11B$3.10B$6.03B$4.97B$2.03B$5.03B$6.83B$6.41B$3.98B$6.71B$1.19B$5.42B
Avg Forecast$8.42B$8.45B$8.18B$6.68B$8.03B$7.79B$7.46B$6.60B$7.35B$7.10B$6.85B$6.05B$6.86B$6.61B$6.49B$9.05B$6.49B$6.35B$6.27B$8.23B$7.47B$5.47B$5.36B$7.48B$5.47B$5.23B$4.98B$6.43B$5.01B$4.65B
High Forecast$8.75B$8.79B$8.50B$6.94B$8.35B$8.10B$7.76B$6.86B$7.64B$7.38B$7.12B$6.26B$6.92B$6.61B$6.49B$10.86B$6.64B$6.40B$6.51B$9.87B$8.96B$5.47B$5.36B$8.97B$5.47B$5.23B$4.98B$7.71B$5.01B$4.65B
Low Forecast$8.24B$8.27B$8.00B$6.54B$7.86B$7.62B$7.30B$6.46B$7.19B$6.95B$6.70B$5.94B$6.81B$6.61B$6.49B$7.24B$6.45B$6.32B$6.13B$6.58B$5.97B$5.47B$5.36B$5.98B$5.47B$5.23B$4.98B$5.14B$5.01B$4.65B
Surprise %-----------------0.38%0.82%0.38%0.81%0.91%0.38%0.67%1.25%1.23%0.80%1.04%0.24%1.17%

9 analysts predict ABBV's average Quarter EBITDA for Dec 23 to be $6.49B, with a high of $6.64B and a low of $6.45B. This is 165.77% upper than AbbVie's previous annual EBITDA (Sep 23) of $2.44B.

AbbVie Net Income Forecast

Dec 27Sep 27Jun 27Mar 27Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20
# Analysts4444444433351377491599131313137777915
Net Income-----------------$1.78B$2.02B$239.00M$2.47B$3.95B$924.00M$4.49B$4.04B$3.18B$766.00M$3.55B$36.00M$2.31B
Avg Forecast$6.95B$6.35B$6.79B$5.04B$6.86B$6.44B$6.30B$5.25B$5.94B$5.69B$5.55B$4.53B$3.74B$5.17B$4.55B$5.40B$4.95B$5.08B$5.02B$4.91B$4.42B$6.33B$5.88B$4.46B$5.81B$5.69B$5.46B$3.40B$5.05B$4.89B
High Forecast$7.31B$6.68B$7.14B$5.29B$7.22B$6.77B$6.63B$5.52B$6.25B$5.98B$5.84B$5.01B$3.88B$5.20B$4.55B$6.48B$4.99B$5.19B$5.28B$5.89B$5.31B$6.33B$5.88B$5.35B$5.81B$5.69B$5.46B$4.08B$5.05B$4.89B
Low Forecast$6.76B$6.17B$6.60B$4.89B$6.67B$6.26B$6.12B$5.10B$5.77B$5.53B$5.40B$4.25B$3.67B$5.15B$4.55B$4.32B$4.90B$4.97B$4.88B$3.93B$3.54B$6.33B$5.88B$3.57B$5.81B$5.69B$5.46B$2.72B$5.05B$4.89B
Surprise %-----------------0.35%0.40%0.05%0.56%0.62%0.16%1.01%0.70%0.56%0.14%1.04%0.01%0.47%

AbbVie's average Quarter net income forecast for Dec 23 is $4.95B, with a range of $4.90B to $4.99B. ABBV's average Quarter net income forecast represents a 178.35% increase compared to the company's last Quarter net income of $1.78B (Sep 23).

AbbVie SG&A Forecast

Dec 27Sep 27Jun 27Mar 27Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20
# Analysts4444444433351377491599131313137777915
SG&A-----------------$3.37B$3.27B$3.04B$3.42B$3.30B$5.41B$3.13B$3.26B$3.08B$3.16B$2.84B$3.23B$2.85B
Avg Forecast$4.28B$4.29B$4.15B$3.39B$4.08B$3.95B$3.79B$3.35B$3.73B$3.61B$3.48B$3.07B$3.48B$3.36B$3.29B$3.76B$3.30B$3.22B$3.18B$3.42B$3.56B$3.53B$3.46B$3.11B$3.53B$3.37B$3.22B$2.72B$3.23B$3.00B
High Forecast$4.45B$4.46B$4.32B$3.53B$4.24B$4.11B$3.94B$3.48B$3.88B$3.75B$3.62B$3.18B$3.52B$3.36B$3.29B$4.51B$3.37B$3.25B$3.31B$4.10B$4.28B$3.53B$3.46B$3.73B$3.53B$3.37B$3.22B$3.27B$3.23B$3.00B
Low Forecast$4.18B$4.20B$4.06B$3.32B$3.99B$3.87B$3.71B$3.28B$3.65B$3.53B$3.40B$3.02B$3.46B$3.35B$3.29B$3.01B$3.27B$3.21B$3.11B$2.73B$2.85B$3.53B$3.46B$2.49B$3.53B$3.37B$3.22B$2.18B$3.23B$3.00B
Surprise %-----------------1.05%1.03%0.89%0.96%0.94%1.56%1.01%0.92%0.91%0.98%1.04%1.00%0.95%

AbbVie's average Quarter SG&A projection for Dec 23 is $3.30B, based on 9 Wall Street analysts, with a range of $3.27B to $3.37B. The forecast indicates a -2.26% fall compared to ABBV last annual SG&A of $3.37B (Sep 23).

AbbVie EPS Forecast

Dec 27Sep 27Jun 27Mar 27Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20
# Analysts4444444433351377491599131313137777915
EPS-----------------$1.01$1.14$0.14$1.40$2.22$0.52$2.52$2.29$1.80$0.43$2.01$0.02$1.31
Avg Forecast$3.92$3.58$3.83$2.84$3.87$3.63$3.56$2.96$3.35$3.21$3.13$2.56$2.11$2.92$2.57$2.25$2.79$2.87$2.83$2.51$3.56$3.57$3.32$3.14$3.28$3.21$3.08$2.81$2.85$2.76
High Forecast$4.12$3.77$4.03$2.99$4.07$3.82$3.74$3.11$3.52$3.37$3.29$2.83$2.19$2.93$2.57$2.26$2.81$2.93$2.98$2.64$3.71$3.57$3.32$3.14$3.28$3.21$3.08$2.81$2.85$2.76
Low Forecast$3.81$3.48$3.73$2.76$3.77$3.53$3.46$2.88$3.26$3.12$3.05$2.40$2.07$2.91$2.57$2.25$2.76$2.80$2.75$2.44$3.46$3.57$3.32$3.14$3.28$3.21$3.08$2.81$2.85$2.76
Surprise %-----------------0.35%0.40%0.06%0.39%0.62%0.16%0.80%0.70%0.56%0.14%0.72%0.01%0.47%

According to 9 Wall Street analysts, AbbVie's projected average Quarter EPS for Dec 23 is $2.79, with a low estimate of $2.76 and a high estimate of $2.81. This represents a 176.53% increase compared to ABBV previous annual EPS of $1.01 (Sep 23).

AbbVie Peer Comparison by Price Target

TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
MRKMerck$98.28$135.8338.21%Buy
LLYEli Lilly and$804.08$1.01K26.12%Buy
PFEPfizer$26.62$32.1720.85%Hold
ABBVAbbVie$175.26$211.2020.51%Buy
AMGNAmgen$281.68$338.2220.07%Buy
JNJJohnson & Johnson$151.15$178.7118.23%Buy
BMYBristol-Myers Squibb$59.05$61.003.30%Hold
GILDGilead Sciences$95.59$88.88-7.02%Buy

ABBV Forecast FAQ

Is AbbVie a good buy?

Yes, according to 32 Wall Street analysts, AbbVie (ABBV) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 22 'Buy' recommendations, accounting for 68.75% of ABBV's total ratings.

What is ABBV's price target?

AbbVie (ABBV) average price target is $211.2 with a range of $203 to $226, implying a 20.51% from its last price of $175.26. The data is based on 32 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will AbbVie stock go up soon?

According to Wall Street analysts' prediction for ABBV stock, the company can go up by 20.51% (from the last price of $175.26 to the average price target of $211.2), up by 28.95% based on the highest stock price target, and up by 15.83% based on the lowest stock price target.

Can AbbVie stock reach $300?

ABBV's average twelve months analyst stock price target of $211.2 does not support the claim that AbbVie can reach $300 in the near future.

What are AbbVie's analysts' financial forecasts?

AbbVie's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $64.56B (high $67.12B, low $63.17B), average EBITDA is $29.88B (high $31.06B, low $29.23B), average net income is $24.86B (high $26.14B, low $24.16B), average SG&A $15.17B (high $15.77B, low $14.84B), and average EPS is $14.03 (high $14.75, low $13.63). ABBV's analysts financial forecasts for the fiscal year (Dec 2027) are as follows: average revenue is $68.57B (high $71.29B, low $67.09B), average EBITDA is $31.73B (high $32.99B, low $31.05B), average net income is $25.13B (high $26.43B, low $24.43B), average SG&A $16.11B (high $16.75B, low $15.77B), and average EPS is $14.18 (high $14.91, low $13.79).

Did the ABBV's actual financial results beat the analysts' financial forecasts?

Based on AbbVie's last annual report (Dec 2022), the company's revenue was $58.05B, which missed the average analysts forecast of $58.57B by -0.88%. Apple's EBITDA was $19.66B, missing the average prediction of $25.78B by -23.73%. The company's net income was $11.84B, missing the average estimation of $21.09B by -43.88%. Apple's SG&A was $15.26B, beating the average forecast of $13.66B by 11.69%. Lastly, the company's EPS was $6.65, missing the average prediction of $13.6 by -51.09%. In terms of the last quarterly report (Sep 2023), AbbVie's revenue was $13.93B, beating the average analysts' forecast of $13.72B by 1.52%. The company's EBITDA was $2.44B, missing the average prediction of $6.35B by -61.53%. AbbVie's net income was $1.78B, missing the average estimation of $5.08B by -65.01%. The company's SG&A was $3.37B, beating the average forecast of $3.22B by 4.61%. Lastly, the company's EPS was $1.01, missing the average prediction of $2.87 by -64.78%